Malvern gene therapy company targeting heart diseases raises $17M
December 06, 2018 at 07:32 AM EST
Xylocor's lead product is a gene therapy for treatment-resistant angina.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.